Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

Company

News
About
Contact

Legal

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

Terms Privacy

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Resistance to TIL therapy in lung cancer mediated by clonal T cell loss and neoantigen escape - MedPath Trial

Home NewsResistance to TIL therapy in lung cancer mediated by clonal T cell loss and neoantigen escape

Resistance to TIL therapy in lung cancer mediated by clonal T cell loss and neoantigen escape

Medical News|May 21, 2025

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Content not available.

Related Coverage

Sources

Resistance to TIL therapy in lung cancer mediated by clonal T cell loss and neoantigen escape

nature.comMay 21, 2025

Cell therapies - Latest research and news | Nature

nature.comMay 21, 2025

Related Coverage

Sources

Top Stories This Week